Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28104077 | 0.82 | MAPT (0.46) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL27531684 | 0.82 | KMT2A (0.53) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL29970206 | 0.82 | CA1 (0.56) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL128193 | 0.82 | CA1 (0.56) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL14953198 | 0.81 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL261504 | 0.81 | MAPT (0.56) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL28185314 | 0.81 | CA1 (0.46) | ALDH1A1HSD17B10TP53HPGDCA12 | |
| SCHEMBL25670705 | 0.81 | PRSS1 (0.42) | KMT2AMEN1ALDH1A1GAAHSD17B10 | |
| SCHEMBL1544934 | 0.81 | KLK1 (0.58) | ALDH1A1HSD17B10TP53HPGDCA12 | |
| Hydrochloric Acid SCHEMBL3284355 | 0.80 | CA1 (0.54) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110255694-A | A kind of method of artificial synthesized redox mediators activation potassium permanganate degradation organic pollutants | 重庆大学 | 2019-09-20 | — | — | CN | disclosed |
| CN-101146529-B | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-08-29 | — | — | CN | disclosed |
| WO-2010019547-A1 | IMINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-02-18 | — | — | WO | disclosed |
| CN-101146529-A | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-19 | — | — | CN | disclosed |
| US-6797824-B2 | UEFUL IN THE DIAGNOSIS AND THERAPY OF AFFECTIVE DISORDERS SUCH AS SCHIZOPHRENIA AND DEPRESSION AS WELL AS CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM | NEUROGEN CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2003-01-23 | — | — | US | disclosed |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6358955-B1 | SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS, PARKINSON*S DISEASE; ANTIDEPRESSANTS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6069251-A | HIGHLY SELECTIVE PARTIAL AGONISTS OR ANTAGONISTS AT BRAIN DOPAMINE RECEPTOR SUBTYPES OR PRODRUGS; DIAGNOSIS AND TREATMENT SCHIZOPHRENIA; ANTIDEPRESSANTS; CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM. | NEUROGEN CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-5712392-A | DOPAMINERGIC AGENTS TREATING SCHIZOPHRENIA, ANTIDEPRESSANTS FOR PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5646281-A | FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5646279-A | USEFUL IN THE DIAGNOSIS AND TREATMENT OF AFFECTIVE DISORDERS, MOVEMENT DISORDERS AND SIDE EFFECTS ASSOCIATED WITH NEUROLEPTIC AGENTS | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5633376-A | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5633377-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996016040-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996010018-A1 | CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5428164-A | Useful for treating and diagnosis of schizophrenia and depression as well as parkinson's disease | NEUROGEN CORPORATION (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0640075-A1 | CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5159083-A | Treatment of schizophrenia, depression, parkinson's disease; side effect reduction | NEUROGEN CORPORATION (US) | 1992-10-27 | — | — | US | disclosed |
| WO-1992012134-A2 | CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | CHRNA4, GRIA4, OPRM1 | KMT2A 1287/4885MEN1 4654/4885NPC1 4505/4885 |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | DRD2, OPRM1, OPRD1 | KMT2A 1336/4885MEN1 4741/4885NPC1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.